Heron Therapeutics | HRTX - 销售和管理费用



金融业
股票价格
USD
资产
USD 252.26M
现金及等价物
USD 20.72M
销售成本
USD 11.12M
流动资产
USD 229.85M
流动负债
USD 92.15M
债务
USD 149.65M
股息收益率
0
EBIT
USD 38K
EBITDA
USD -3.88M
员工
126
EPS每股收益
USD -0.02
股本和储备
USD 6.91M
销售毛利
USD 29.47M
债务利息支出
USD 600K
利息收入
USD 433K
贷款资金
USD 140.64M
市值
USD 49.9M
净收入
USD -2.95M
营业费用
USD 40.55M
营业利润
USD 38K
普通股股本
USD 188.31M
税前利润
USD -2.95M
销售收入
USD 40.59M
销售和管理费用
USD 23.74M
股票
USD 54.57M
贸易债权人
USD 11.64M
应收帐款人
USD 89.59M


销售和管理费用 更改 日
ALKERMES USD 196.64M 67.96M 2026-06
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amarin USD 18.97M 1.03M 2025-12
ANI Pharmaceuticals USD 91.66M 18.01M 2026-06
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
Eisai JPY 114.83B 4.71B 2026-06
Emergent BioSolutions USD 182.8M 82.3M 2023-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 247.47M 208K 2026-06
Ligand Pharmaceuticals USD 29.12M 8.29M 2026-06
Merck USD 2.89B 219M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Omeros USD 11.32M 2.48M 2024-09
Pacira USD 91.81M 7.93M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Veracyte USD 55.71M 4.87M 2026-06
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06